据病友心与心愿消息提供，美国ACT先进细胞技术公司CEO MR rabin将于9月13和14日在两个重要会议上提供公司正在进行的两个实验的最新消息。到时候网上有直播，有精通英文的网友可以第一时间知道实验进展。关于实验（胚胎干细胞治疗少年性黄斑变性和干性黄斑变性）上次的最新消息是7月份的，实验已经进行，患者耐受情况良好，但具体内容没有公布，期待下周的最新消息。
Mr. Rabin will provide updates on the company’s two ongoing human clinical trials using hESC-derived RPE cells to treat macular degeneration and other programs.
Mr. Rabin will present at the Rodman & Renshaw 13th Annual Healthcare Conference on Tuesday, Sept. 13, at 10:25 a.m. EDT, at the Waldorf Astoria.
是的，部分黄斑变性类眼底病先获得治疗，RP病患者还需要等待。干性黄斑变性如果能治疗了，估计一些RP病患者能获益。
第一个会议已经结束，但网上没看到相关的内容，第二个会议由于时差的关系，在北京时间明天凌晨6点前结束，有精通英文的朋友可以找下内容，Mr. Rabin will also present at Terrapinn’s Stem Cells USA & Regenerative Medicine Congress 2011, on Wednesday, Sept. 14, at 2:35 p.m. EDT at the Sheraton Boston Hotel.作者: 陶黎 时间: 2011-9-17 18:47
ACT’s Director of Regulatory Affairs Edmund Mickunas to Present at Phacilitate Cell & Gene Therapy Forum in Singapore; Reflects Growing Interest in Company and Its Programs in East AsiaGreetings,
ACT’s Director of Regulatory Affairs, Edmund “Ed” Mickunas, will be presenting on the company’s behalf at a major industry conference, the “Phacilitate Cell & Gene Therapy Forum Asia 2011,” Sept. 19-21, in Singapore.
Ed’s presentation will focus on regulatory issues surrounding human clinical trials in the field of regenerative medicine, such as our two recently-initiated trials at UCLA’s Jules Stein Eye Institute using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) for the treatment of Stargardt’s Disease and dry age-related macular degeneration (dry AMD). Ed will also discuss ACT’s preparation for our past investigational new drug (IND) application filings for these two trials.
Asia, particularly the vast market opportunity represented by the emerging markets of East and Southeast Asia, has become a major priority for ACT as a company. We are proud of the progress made thus far in our partnership with CHA Bio & Diostech Co, Ltd. (“CHA Biotech”), a leading South Korea-based biotechnology company. We are also exploring opportunities in other major markets in the region, specifically China, and are making progress in pursuing opportunities there. You may remember that earlier this year we announced that we are to be issued a broad patent on hESC-derived RPE cells in China. We will keep you updated on other goings-on for the company in East Asia and elsewhere.
Additionally, access to my recent presentation at the Rodman & Renshaw Global Investment Conference in New York is available at this link (registration required), and access to my presentation at Terrapinn’s Stem Cells USA and Regenerative Medicine Congress in Boston is available here (PDF).
Thank you.
Gary Rabin
Chairman and CEO
Advanced Cell Technology, Inc.作者: 山重水复 时间: 2011-9-18 14:03
